Oncotelic Therapeutics (OTCQB: OTLC) announced a strategic partnership with TechForce Robotics to advance commercialization of its PDAOAI-enabled, GMP-compliant robotics platform designed for pharmaceutical manufacturing and regulated environments. The integrated system combines Oncotelic’s proprietary AI capabilities with TechForce’s robotics and manufacturing expertise to enable automated material handling, real-time monitoring and compliance workflows, with scalability for broader deployment, as the companies move forward under a joint development, manufacturing and licensing agreement to address growing demand for intelligent, compliant automation solutions.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer